Clinical response under MEK inhibitor alone in metastatic melanoma with a novel fusion involving the RAF1 gene-Reference-Cited by-同舟云学术

Clinical response under MEK inhibitor alone in metastatic melanoma with a novel fusion involving the RAF1 gene

Published:2023-03-03 Issue:3 Volume:33 Page:247-251
ISSN:0960-8931
Container-title:Melanoma Research
language:en
Short-container-title:

Author:

Boileau Marie¹²³,Descarpentries Clotilde²⁴,Delzenne Guillaume¹³,Trentesaux Victorine¹,Greliak Anna¹²,Jamme Philippe¹²,Marchetti Philippe²³⁵,Mortier Laurent¹²

Affiliation:

1. Department of Dermatology, Service de Dermatologie, Hôpital C. Huriez, CHU de Lille

2. Department of Medicine, Université de Lille

3. UMR 1172 INSERM, Université de Lille

4. Department of Biochemistry and Molecular Biology ‘Hormonology Metabolism Nutrition Oncology’, CHU de Lille and

5. Department of Tissu Bank, Banque de tissus, Centre de biologie et pathologie, CHU de Lille, Lille, France

Abstract

Currently, in the absence of BRAFV600 mutation, the management of advanced melanomas is based on immunotherapies, but only half of the patients are responders. RAF1 (also named CRAF) fusions occur in 1–2.1% of wild-type melanomas. Preclinical data suggest that the presence of RAF fusion may be sensitive to MEK inhibitors. We report the case of a patient with an advanced melanoma harboring anEFCC1–RAF1fusion who showed a clinical benefit from and a partial response to a MEK inhibitor.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Dermatology,Oncology

Reference32 articles.

1. The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin.;Whiteman;Pigment Cell Melanoma Res,2011

2. Pembrolizumab versus ipilimumab in advanced melanoma.;Robert;N Engl J Med,2015

3. Nivolumab in previously untreated melanoma without BRAF mutation.;Robert;N Engl J Med,2015

4. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.;Postow;N Engl J Med,2015

5. Improved overall survival in melanoma with combined dabrafenib and trametinib.;Robert;N Engl J Med,2015

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relevance of detection of RAF fusion transcripts in pan-negative melanoma in routine practice;Melanoma Research;2024-02-07

2. The role of CRAF in cancer progression: from molecular mechanisms to precision therapies;Nature Reviews Cancer;2024-01-09

3. Ipilimumab/nivolumab/trametinib;Reactions Weekly;2023-12-09